CVKD (Cadrenal Therapeutics) Cash And Cash Equivalents : $7.34 Mil (As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is Cadrenal Therapeutics Cash And Cash Equivalents?

Cadrenal Therapeutics's quarterly cash and cash equivalents increased from Sep. 2024 ($4.36 Mil) to Dec. 2024 ($10.02 Mil) but then stayed the same from Dec. 2024 ($10.02 Mil) to Mar. 2025 ($7.34 Mil).

Cadrenal Therapeutics's annual cash and cash equivalents increased from Dec. 2022 ($0.03 Mil) to Dec. 2023 ($8.40 Mil) and increased from Dec. 2023 ($8.40 Mil) to Dec. 2024 ($10.02 Mil).

Cadrenal Therapeutics Cash And Cash Equivalents Historical Data

The historical data trend for Cadrenal Therapeutics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cadrenal Therapeutics Cash And Cash Equivalents Chart

Cadrenal Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

Cash And Cash Equivalents

0.03

8.40

10.02

Cadrenal Therapeutics Quarterly Data
	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Cash And Cash Equivalents	Get a 7-Day Free Trial								6.57	5.04	4.36	10.02	7.34

Cadrenal Therapeutics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Cadrenal Therapeutics (NAS:CVKD) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Cadrenal Therapeutics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Cadrenal Therapeutics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Cadrenal Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadrenal Therapeutics Inc (NAS:CVKD) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

822 A1A North, Suite 306, Ponte Vedra, FL, USA, 32082

Website

https://www.cadrenal.com

Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.

Executives

John Raymond Murphy	director	233 S PATTERSON AVE, SPRINGFIELD MO 65802
Quang X Pham	director, 10 percent owner, officer: CEO and Chairman	89 MELROSE DRIVE, MISSION VIEJO CA 92692
Robert Lisicki	director	C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Douglas W Losordo	officer: Chief Medical Officer	13 FOX MEADOW RD, SCARSDALE NY 10583
Steven Zelenkofske	director	120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920
Matthew K Szot	officer: Chief Financial Officer	802 NORTH DOUTY STREET, HANFORD CA 93230
Glynn Wilson	director	2483 NE JULEP STREET, ISSAQUAH WA 98029